Modeling cardiac function and arrhythmia is crucial to the understanding of disease and the safety and efficacy of potential treatments. Initiatives like the Comprehensive in vitro Proarrhythmia Assay (CiPA) aim to improve in vitro predictivity of arrhythmogenic risk. What is CiPA?
The Maestro Pro is designed to measure cardiomyocyte function and provides detailed, reproducible electrophysiological data while requiring only basic cell culture techniques. Capable of measuring the electrical, contractile, and propagation activity of cardiac cells, one system can provide a wealth of information. See why the Maestro Pro was the most accurate and reproducible at predicting arrhythmogenic risk.
Watch the short video on the multi-site CiPA Phase II validation study results. See why the Maestro Pro was the most reliable and reproducible system on the market.
Predict arrhythmogenic risk with acute or chronic exposures. See the results of the two CiPA studies. Detect early after depolarizations and subtle action potential changes. Track signal propagation across the cardiac syncytium.
LEAP technology enables non-invasive, label-free monitoring of the cardiac action potentials in a high-throughput format.
